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Recurrent, advanced stage cutaneous squamous cell carcinoma (cSCC) is uncommon with limited publications on patient
outcomes. A retrospective study including patients who underwent surgical resection for recurrent, advanced stage cSCC of the
head and neck was performed (n = 72). Data regarding tumor site, stage, treatment, parotid involvement, perineural invasion,
positive margins,metastasis,and disease-free survival was analyzed. The majority of patients were male (85%) and presented with
recurrent stage III (89%) cSCC. Two-year disease-free survival was 62% and decreased to 47% at 5 years. Parotid involvement,
positive margins, nodal metastasis, or the presence of perineural invasion did not correlate with decreased survival (P>. 05).
Distantmetastasiswasa strongindicatorofpoor overallsurvival(P<. 001).Adjuvant postoperative radiotherapy did notimprove
overall survival (P = .42). Overall survival was poor for patients with advanced recurrent cSCC despite the combined treatment
with surgery and radiotherapy.
1.Introduction
Nonmelanoma skin cancer (NMSC) is the most common
diagnosed malignancy in the United States with more than
one million new cases reported each year [1]. Basal cell
(BCC) and cutaneous squamous cell carcinoma (cSCC)
comprise nearly all of the NMSCs. The majority of lesions
(80–90%) arise in the sun exposed areas of the head and
neck [2] and are successfully treated by complete tumor
excision. A small percentage of NMSCs, mostly cSCCs,
are refractory to standard surgical resection [1, 3]. Several
outpatient-based studies have demonstrated a low incidence
of nodal metastasis (2-3%) in patients with cSCC [4, 5].
Most tertiary care center-referred patients, however, present
with recurrent disease and are at increased risk for neck
metastasis, poorlocal control,and furthercancerrecurrence.
High risk prognostic indicators include size, anatomic site,
recurrence, history of radiation, immunosuppression, and
perineural invasion [6]. It is unknown whether the same risk
factors can be applied to determine prognosis in patients
with recurrent disease.
In the present study, we evaluate outcomes in patients
with advanced, recurrent cSCC of the head and neck. In the
majority of cases, the treatment recommendations for this
patient population are surgery and adjuvant radiotherapy
[7]. Although no single variable can dictate treatment,
this study sought to identify further predictive factors and
provide guidance for counseling patients with aggressive
head and neck cSCC.
2.Materialsand Methods
A retrospective review of all patients (n = 72) who presented
with recurrent, advanced stage (III or IV) cSCC of the
head and neck between June 1998 and December 2007 was
performed at The University of Alabama at Birmingham
following Institutional Review Board approval. Tumors were
staged according to the American Joint Committee on2 Journal of Skin Cancer
Cancer (AJCC) guidelines, and histology was conﬁrmed by
pathology. Tumors were divided into 5 diﬀerent anatomic
sites: face, neck, ear, periauricular area, and scalp. Lesions
occurring on the face included forehead, periorbital, nose,
lip, and chin. Periauricular lesions were deﬁned as lesions
occurring on the temple, cheek, or postauricular area.
All patients underwent aggressive surgical resection. This
included parotidectomy for cases in which parotid involve-
ment was suspected on preoperative imaging or clinical
exam. Parotidectomy ranged from superﬁcial to radical
parotidectomy with sacriﬁce of the facial nerve. The major-
ity of patients required neck dissection and postoperative
radiation. Selective, modiﬁed, or radical neck dissection was
performed at the time of resection or in a staged procedure.
Neck dissection was indicated when nodal metastasis was
suspected on preoperative imaging or when the patient
presented with an advanced T classiﬁcation of their lesion.
Postoperative radiation was recommended for patients with
large cutaneous malignancies when more than one positive
node was identiﬁed on neck dissection, when negative
surgical margins could not be obtained, or in the presence of
perineural or lymphovascular invasion. Histological margins
were deﬁned as negative if the advancing tumor edge was
≥4mm from the line of surgical excision and positive if less
than 4mm. All cutaneous defects were repaired either by
primary closure, split thickness skin graft, local or regional
ﬂap coverage, or free tissue transfer.
Demographic characteristics, including patient age, gen-
der, a history of immunosuppression, previous treatment,
and time to recurrence, were recorded. Prognostic indicators
including tumor site, size, perineural invasion, positive mar-
gins, or histologic grade were reviewed. Outcomes measured
consisted of disease-free survival and cancer recurrence.
Descriptive variables are reported as means (±SD) and
categorical variables as percentages. Descriptive statistics
were compared by general linear models for normally
distributed variables orthe Kruskal-Wallis test for otherwise.
The relationship between patient clinical and treatment
factors and disease-speciﬁc survival was calculated using the
Kaplan-Meier method. Survival time was calculated as the
interval from date of surgery to date of death or date of
last followup. Deaths due to other causes were censored for
these analyses. A P-value of <.05 was considered statistically
signiﬁcant. Statistical analysis was performed using SAS
Version 9.2 software (SAS Institute Inc., Cary, NC).
3.Results
Between 1998 and 2007, there were 72 patients identiﬁed
who underwent surgical resection for recurrent, advanced
stage cSCC. The majority of patients were male (84.7%),
presented with stage III disease (88.8%), and had undergone
previous surgical resection (76.5%). Median time from pre-
vious skin cancer diagnosis to presentation with recurrence
was 5.7 months (range, 1–41 months). Mean tumor size was
3.4cm in largest dimension (±SD 2.07). The majority of
lesions occurred on the ear or periauricular area (65.2%)
and were classiﬁed as T4 lesions (83.3%) invading into deep
extradermal structures (Table 1). Ten patients had a history
Table 1: Patient characteristics.
Characteristic n (%)
Age-years
Mean (range) 71 (42–93)
Gender
Male 61 (85)
Female 11 (15)
Tumor subsite
Face 19 (27)
Forehead 5
Periorbital 4
Nose 8
Chin 1
Lip 1
Periauricular 34 (47)
Cheek 13
Temple 18
Postauricular 3
Ear 13 (18)
Scalp 3 (4)
Anterior 2
Posterior 1
Neck 3 (4)
T classiﬁcation
T1 1 (1)
T2 5 (7)
T3 4 (6)
T4 60 (83)
Tx 2 (3)
TMN Stage
III 64 (89)
IV 8 (11)
of immune suppression due to lymphoma or leukemia
(n = 6), rheumatoid arthritis (n = 1) or were currently
maintained onimmunosuppressive medicationsduetoprior
transplant (n = 3).
No diﬀerence in margin status was observed between the
various tumor sites (P = .48). Perineural invasion, a known
risk factor for recurrence and metastasis, occurred in 36.9%
of patients. Patients with cSCC of the ear and periauricular
area were more likely to demonstrate perineural invasion on
surgical pathology in comparison to all other sites (P = .06).
Although perineural invasion did not signiﬁcantly correlate
with tumor site or size, patients with this ﬁnding were more
likely to have parotid involvement (P = .04). A total of
39 patients (54.1%) underwent superﬁcial (n = 16), total
(n = 11) or radical (n = 12) parotidectomy. Four patients
had undergone previous parotidectomy for positive nodal
metastasis. Parotid involvement, either by direct extension
or nodal metastasis, was conﬁrmed by surgical pathology in
92.3% of cases (n = 36).
The majority of patients with parotid involvement
underwent neck dissection (92.3%). Neck dissection wasJournal of Skin Cancer 3
performed in 66.7% of all patients. The majority (64.5%)
underwent selective (n = 31) or modiﬁed radical (n =
14) neck dissection. One patient required a radical neck
dissection. Another patient with a posterior scalp lesion
had previously undergone an extended posterior triangle
dissection. Three patients had undergone previous neck
dissections. Positive nodal metastasis occurred in 43.7%
(n = 21/48) of patients, and nearly all cases occurred in
patients with advanced T classiﬁcation (83.3%) and those
with parotid involvement (85.7%, n = 18/21). The majority
of nodes were located in levels I–III (95%). No positive
nodes were identiﬁed in level IV, and one case of nodal
metastasis occurred in level V (Table 3). Nodal metastasis
did not correlate with tumor size, though a larger percentage
of patients with cSCC of the ear demonstrated neck disease
(66.7%) in comparison to other sites (P = .14). Eight
patients had evidence of distant metastasis at the time of
surgical resection. Distant metastasis did not correlate with
perineural invasion, original tumor site, size, or parotid
involvement at the time of surgical resection (P>. 05). The
histologic grades of the tumors consisted of 19% (n = 14)
well diﬀerentiated, 56% (n = 40) moderately diﬀerentiated,
8% (n = 6) moderate-poorly diﬀerentiated, and 17%
(n = 12) poorly diﬀerentiated. There was not a statistically
signiﬁcant relationship found between histologic grade and
survival (data not shown).
All defects were closed either by primary closure or split
thickness skin graft (n = 23), local or regional ﬂap (n = 7),
or free tissue transfer (n = 42). One patient underwent
pectoralis major myocutaneous ﬂap reconstruction, and 6
patients required local cervicofacial ﬂap coverage. Patients
withlargerdefectstypicallyrequiredfree ﬂap reconstruction.
The radial forearm free ﬂap (n = 13) and anterolateral
thigh (n = 12) were most commonly utilized for soft tissue
coverage. In cases in which bony reconstruction was also
required, the osteocutaneous radial forearm free ﬂap (n = 4)
and ﬁbula (n = 2) were employed (Table 2).
The majority of patients underwent postoperative radi-
ation (66.7%) as a result of advanced stage disease. Fifteen
patients had undergone previous radiotherapy, and 3 under-
went both pre- and postoperative radiation. The majority
of patients with positive margins underwent postoperative
radiation. Three patients had prior radiation therapy and
were unable to tolerate the cytotoxic eﬀects of a second
course of radiation, and two electively declined further ther-
apy. Three patients with perineural invasion did not undergo
postoperative radiotherapy based on personal preference.
Mean time to follow up was 18.5 months. Forty percent
of patients (n = 28) developed local (67.8%, n = 19),
regional (25%, n = 7) or distant metastasis (14.2%; n = 4)
during the followup period. Median time to cancer recur-
rence was less than 7 months (6.5, range 1–41 months). One
patient had local recurrence and developed lung metastasis
while another patient developed both recurrent neck disease
and lung metastasis. Although not statistically signiﬁcant,
patientsweremorelikelytorecuriftheypresentedwith cSCC
of the ear or periauricular area (P = .06), demonstrated
positive nodal metastasis at the time of neck dissection
(P = .14), or did not undergo postoperative radiotherapy
Table 2: Free ﬂaps used for cutaneous defect reconstruction.
Flap type n
ALT 12
Latissimus 3
Rectus 8
RFFF 13
Fibula 2
OCRFFF 4
ALT: anterolateral thigh; RFFF: radial forearm free ﬂap; OCRFFF: osteocu-
taneous radial forearm free ﬂap.
Table 3: Patterns of cervical lymph node metastasis.
Level n (%)
I 6 (25)
II 12 (50)
III 5 (20)
IV 0 (0)
V1 ( 5 )
(P = .18). Margin status, a history of immunosuppression,
and perineural invasion did not predict cancer recurrence.
Two-year disease-free survival was 62.2% and was
reduced to 47.2% at 5 years (Figure 1). Age greater than
65 (P = .34), male gender (P = .06), immunosup-
pression (P = .22), and patients with a previous history
of radiation (P = .4) tended towards worse survival
outcomes. Surprisingly, tumor characteristics including site,
size (greater than 3.4cm), parotid involvement, perineural
invasion, or positive margins following resection had no
inﬂuence on disease-free survival. Two-year disease-free
survival for patients with positive nodal metastasis was
47.7% versus 72.9% for those without neck disease (P =
.14) (Figure 2). Although locoregional metastasis was not
a signiﬁcant predictor of survival, distant metastasis noted
within 30 days of surgical resection was associated with poor
prognosis (P<. 001). No patient with distant metastasis
survived beyond 13 months. Most patients required free
ﬂap reconstruction and postoperativeradiation foradvanced
disease. Patients who underwent free ﬂap reconstruction
tended towards worse survival outcomes (P = .24). Despite
aggressive surgical resection, postoperative radiation was not
shown to aﬀect long term disease-free survival (P = .42)
or repeat cancer recurrence (P = .85) for this patient pop-
ulation. Although not statistically signiﬁcant, patients with
cervical metastasis who underwent postoperative radiation
had improved locoregional control (68% versus 25%, P =
.14) when compared to those who underwent surgery alone.
4.Discussion
Nonmelanoma skin cancer is the most common malignancy
worldwide with over 140,000 cases of cSCC diagnosed each
year in the United States alone [8]. The incidence of regional
metastasis amongpatientswith cSCCrangesfrom0.5to16%
[4]andcanresultinpotentiallyfatalconsequences.Although
a number of factors have been identiﬁed as high risk4 Journal of Skin Cancer
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Figure 1: Overall disease-free survival for patients with advanced
recurrent cutaneous squamous cell carcinoma.
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Figure 2: Disease-free survival for patients with and without
positivenodalmetastasis.Two-yeardisease-freesurvivalforpatients
with regional disease was 47.7% versus 72.9% for those without
regional metastasis (P = .14).
prognostic indicators for cancer recurrence and metastasis,
most studies to date have only evaluated primary cSCC. In
contrast, the majority of patientspresenting to a tertiary care
center have undergone previous skin cancer treatment and
subsequently developed a second primary or recurrence. A
diagnosis of recurrent cSCC alone confers a more aggressive
tumor subtype [9], yet identifying factors associated with
poor outcome is essential for patient management and
decision making.
In the present study, we review tumor characteristics,
prior treatment, and outcomes in patients with recurrent,
advanced stage cSCC and evaluate the role of postopera-
tive radiotherapy. Surgery combined with radiation is the
recommended treatment in most cases of advanced disease
[7]. In a study by Veness et al., improved locoregional
control and disease-free survival (73% versus 54%, P =
.004) were achieved in patients who received adjuvant
radiotherapy compared to surgery alone [10]. In another
series, 5-yeardisease-free survival was signiﬁcantly improved
for patients undergoing adjuvant radiotherapy following
surgical resection (73% versus 18%, P = .001), and
locoregional control was maintained in 77% of patients
[11]. Both studies included patients with parotid or cervical
metastasis. Nearly 50% of all patients in this study presented
with parotid involvement, and 30% had cervical metastasis.
All patients underwent surgical resection, and most (66.7%)
had postoperative radiation. Postoperative radiation did not
have an impact on overall disease-free survival (P = .42)
or cancer recurrence (P = .85). Although not statistically
signiﬁcant, patients who presented with cervical metastasis
and received adjuvant radiotherapy in addition to surgical
resectionhadimprovedlocoregionalcontrolwhencompared
to those who underwent surgery alone (68% versus 25%,
P = .14). Adjuvant radiotherapy appears to provide some
beneﬁt in patients with advanced, recurrent cSCC though
the risk for repeat recurrence is high given the aggressive
nature of these neoplasms. The role for systemic therapy in
the treatment of recurrent, advanced stage cSCC remains
unknown. Althoughtherehavebeensome casereports citing
improved outcomeswith the addition of cetuximab [12–14],
the majority of publications on targeted therapies against
EGFR and its tyrosine kinase have demonstrated limited
improvement in the mortality of patients with advanced
disease when used as monotherapy [15–19].
The median time from previous skin cancer diagno-
sis to presentation with initial recurrence was only 5.7
months (range, 1–41 months). This is likely due to the
patient population being comprised of advanced, recurrent
cutaneous squamous cell carcinomas, and as a result, this
cohort of patients had very aggressive disease. The rapid
recurrence of the disease reﬂects the malignant biology of
late stage cSCC. In addition, nearly 40% of patients in
this series developed a second recurrence with the majority
occurring locally (68%). Distant metastasis noted in the
immediate postoperative period was associated with poor
prognosis (P<. 001). Median time to cancer recurrence
was 6.5 months, and overall 2-year disease-free survival was
62%. Although not statistically signiﬁcant, patients from the
present study were more likely to recur if they had cSCC
of the ear or periauricular area (P = .06), demonstrated
cervical metastasis on surgical pathology (P = .14), or
did not undergo postoperative radiotherapy (P = .18).
Previous studies have demonstrated a higher incidence of
nodal metastasis among patients with lesions located on
or around the ear as a result of lymphatic drainage to the
parotid gland [20, 21]. In the present study, nearly half
of all patients with parotid involvement either by direct
extension or nodal metastasis also demonstrated cervical
disease. Multiple studies have demonstrated that patients
with parotid involvement are at a high risk for cervical
metastasis [9, 22]. In a study by Ying et al., 44% of patients
with parotid metastasis also had positive cervical nodes [23].
Therefore it is recommended that all patients with parotid
metastasis undergo selective neck dissection.
Themajorityofpatientsinthisseries underwentselective
neck dissection which included levels I–III. Fifty percent of
the nodal metastasis were located in level II. This ﬁnding isJournal of Skin Cancer 5
similar to what a recent article published, where nearly 80%
of all positive nodal metastasis from cSCC were located in
level II [24]. Although parotid involvement did not have an
inﬂuence on disease-free survival in this patient population,
the 2-year disease-free survival for patients with cervical
metastasis was 48% versus 73% for those without neck
disease (P = .14). In the study by Clayman et al., 3-year
disease-free survival was 69% for patients with lymph node
involvement versus 87% for those without nodal disease
(P = .09)[25].Cervicalmetastasis seemingly confers a worse
prognosis for patients with recurrent disease. Appropriate
neckdissectionshouldbeemployedinpatientswithevidence
of cervical metastasis or in the presence of parotid involve-
ment. If parotid involvement occurs and a neck dissection is
not performed then radiation should also be directed at the
neck due to the high risk of cervical metastasis in patients
with both primary and recurrent disease.
Perineural invasion and tumor size have been considered
high risk factors in patients with primary disease [9]. In a
study by Clayman et al., patients with recurrent carcinoma
weremorelikelytopresentwithlargertumorswhich invaded
beyond subcutaneous tissues and which demonstrated per-
ineural (24%) and lymphovascular invasion [25]. Mean
tumor size for patients presenting with recurrent disease
in our study was 3.6cm, and the majority were T4 lesions
(83%). In addition, perineural invasion occurred in 37% of
patients. Patients with cSCC of the ear and periauricular
area were more likely to demonstrate perineural invasion on
surgical pathology in comparison to all other sites (P = .06),
and patients with perineural invasion were more likely to
have parotid involvement (P = .04). It has previously been
demonstrated that there is a signiﬁcant increase in both
nodal and distant metastasis for patients with perineural
invasion when compared to those without [26]. Similarly,
tumor size has been associated with an increased risk of
metastasis: 30% for tumors>2cmversus9% for those <2cm
[27]. Perineural invasion and tumor size did not inﬂuence
survival rates in this patient population. These results may
be related to the fact that all these patients had high
risk prognostic factors and received postoperative radiation
whichresultedinsomeimprovementinlocoregionalcontrol.
It could also be that recurrent cSCC represents a more
aggressive tumor subtype, and these patients all presented
with advanced disease.
5.Conclusions
Recurrent advanced stage cSCC confers a poor prognosis
with an increased risk for parotid involvement, nodal
metastasis, and poor locoregional control. Despite aggressive
surgical resection including parotidectomy and neck dissec-
tion followed by postoperative radiotherapy, 5-year disease-
free survival rates are less than 50%. Patients presenting with
recurrent disease should be appropriately counseled with
regards to outcome and treatment recommendations.
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